Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.

spinal cord injury pain, post-herpetic neuralgia, and multiple sclerosis. Data for central neuropathic pain were limited, but NNTs were calculated for many peripheral neuropathic pain conditions.

LONDON - OKYO Pharma Limited (NASDAQ: OKYO), a biopharmaceutical company with a market capitalization of $35.05 million ...

Under this condition, which can result from traumatic injuries, infections, metabolic problems, or could be inherited due to ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...

Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose ...

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit ...

A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.

A dysfunctional signaling pathway in the hippocampus has been linked to chronic pain-related memory impairment in mice.